Deep Origin
Drug Discovery AI · Drug Discovery
4open roles
$29.4Mlatest round · Venture round · Mar 2024 · 2 yr ago
1backers · SmartGateVC
50+team · employees, estimated range
Overview
Accelerate drug discovery with physics-based AI. Deep Origin combines simulations and machine learning to predict molecular properties and bring therapeutics to patients faster.
Key facts
As of Nov 13, 2026, Alion lists 4 open roles at Deep Origin. Deep Origin is headquartered in Woodbury, United States. It was founded in 2023. The latest round is Venture - Series Unknown of $29.4M, announced in 2024.
- Open roles
- 4Job postings Alion tracks, as of Nov 13, 2026
- Headquarters
- Woodbury, United StatesAlion company profile, updated Nov 13, 2026
- Founded
- 2023Alion company profile, updated Nov 13, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $29.4MSum of 1 equity round Alion knows
- Latest round
- Venture - Series Unknown · $29.4M · Mar 11, 2024SEC Form D filing · sec.gov
- Technologies in its job postings
- 10Named in its job postings
Official records
Funding and backers
Total raised
$29.4M
1 round on record
Latest round
$29.4M
Venture round · Mar 2024 · 2 yr ago
Team
51-200
employees, estimated range
Hiring now
4
+2 posted in 30 days
Backers
1
SmartGateVC
The money's age
Long since its last round
32 months since the last round · and hiring
Momentum
35/100
hiring for its size, in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 5
Launched Deep Origin Introduces Novel Virtual Screening Architecture; Achieves 100-fold Hit Rate Jump on Challenging Target · The Manila Times
Mar 11, 2024
Raised a round Venture round $29.4M · SEC Form D
2023
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2024 | $29.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Deep Origin Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Michael AntonovExecutive Officer, DirectorSEC Form D
Dmitriy Matthew ShlosbergExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Boltz is a public benefit company building AI-powered molecular modeling tools to make biology programmable and accelerate drug discovery…
MOLCURE is an AI company that accelerates drug discovery by combining machine learning, biotechnology and robotics. Its antibody discovery…
AI-powered in silico toxicology platform for drug discovery. Predict mutagenicity, hERG, DILI, ADME and 55+ models from SMILES…
Xaira Therapeutics uses generative models for protein design and drug discovery. It launched with one of the largest initial funding rounds…
From idea to drug molecule in days™. Tell our agent your target and it will handle the rest. The first fully autonomous drug discovery…
Novogaia is an applied AI drug discovery company that builds machine learning systems to decode the chemistry of natural organisms…
Jobs
Remote (United States, United Kingdom)
Python
Machine Learning
Life Sciences
Mass Spectrometry
Apply
≈ $104k – $205k per year (Estimated) · In office · South San Francisco
CRISPR
qPCR
PCR
Flow Cytometry
Western Blot
Cell Culture
Design of Experiments
Apply
≈ $185k – $352k per year (Estimated) · In office · Full-Time · South San Francisco
Apply
≈ $123k – $233k per year (Estimated) · Remote (United States) · Full-Time · San Francisco
Machine Learning
Apply
Growth
Hiring Momentum
25/100
Slowing
Open positions
4
0 opened / 0 closed in 30 days
Median time-to-fill
39 days
faster than 35% of the market
ATS activity
Every ~6 hours
Today
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
40% ▲
Product
20% ▲
Sales
20% ▼
Science & Research
20% ▲
Financials
Total raised
$29.4M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $29.4M | Details |
People
Michael Antonov
Executive Officer, Director
Dmitriy Matthew Shlosberg
Executive Officer, Director
Garegin Papoian
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Deep Origin over the last 12 months, by layer, with the share of postings for each.
Technologies in use
10
Postings analysed
3
Stack modernity
60/100
Languages
Python
Sign in to see how your skills match this stack
Sign In
Full Deep Origin tech stack
10 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
SmartGateVCVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Drug Developers Deploy In Silico Drug Safety Prediction Models From Deep Origin's ARPA-H-Funded PREDICTS Consortium
ImmVue, Synko, Sanford Burnham Prebys, and SyzOnc are running Deep Origin's ADMET predictions across millions of compounds to prioritize discovery...
Read more
Report
Deep Origin宣称AI药物发现平台取得重大突破_手机网易网
DeepOrigin本月宣布其AI药物发现框架在一种癌症免疫疗法酶的筛选中实现了近31%的命中率比常见的基于机器学习的方法高出近100倍该公司表示这一突破得益于其将物理模拟与AI方法相结合的研究路径其中包括新型共折叠模型co-foldingmodel
Read more
Report
'Molecular glue' turns a cancer driver into a built-in kill switch in Stanford Medicine study
A lymphoma driver called BCL6 suppresses the expression of cell death genes. A new molecule designed at Stanford Medicine blocks its activity and activates downstream genes to trigger cell death.
Read more
Report
Deep Origin Introduces Novel Virtual Screening Architecture; Achieves 100-fold Hit Rate Jump on Challenging Target
Deep Origin Introduces Novel Virtual Screening Architecture; Achieves 100-fold Hit Rate Jump on Challenging Target
Read more
Report
Deep Origin Introduces Novel Virtual Screening Architecture Achieves 100-Fold Hit Rate Jump On Challenging Target
Deep Origin Introduces Novel Virtual Screening Architecture Achieves 100-Fold Hit Rate Jump On Challenging Target. In a blind test, Deep Origin
Read more
Report
Deep Origin
Deep Origin docking software and molecular dynamics simulations pinpointed the lead compound from a 17-compound library
Read more
Report
Deep Origin
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Deep Origin reflects the research output of authors from Deep Origin who published articles in the 145 journals included in the Nature
Read more
Report
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
South San Francisco
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Woodbury
United States
HQ
South San Francisco
United States
Regional office
6000 Shoreline Ct. Ste 325,South San Francisco, CA 94080.
2 open roles 2 posted in 90 days 50% engineering 50-200 est. staff
hires for Product, Science & Research
6000 Shoreline Ct. Ste 325, South San Francisco, 94080
How to cite this page
Alion, "Deep Origin: key facts", as of Nov 13, 2026. https://alion.io/company/deeporigin-2
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0